Summary
One provided claim is supported by the label excerpt in WARNINGS (smoking; age >35). Other claims in the user’s list were not evaluated against label text provided, and the product-identification/interchangeability/website-source claims are not supported by the supplied prescribing information excerpts.
Category Scores
Accurate Statements
Cigarette smoking increases the risk of serious cardiovascular events with combination oral contraceptive use, and combination oral contraceptives should not be used by women over 35 who smoke.
Supported by Isibloom label section 5 WARNINGS: “Cigarette smoking increases the risk of serious cardiovascular events... This risk increases with age, particularly in women over 35 years of age... For this reason, combination oral contraceptives... should not be used by women who are over 35 years of age and smoke.”
Unsupported Statements
Isibloom is a brand name used for a type of contraceptive pill that contains ethinyl estradiol and desogestrel.
The provided prompt’s label excerpts do not explicitly state this phrasing as a brand/type description. While the drug/active ingredient list in the prompt indicates desogestrel and ethinyl estradiol, that is not part of the supplied prescribing information excerpts.
Isibloom is a combined oral contraceptive containing ethinyl estradiol and desogestrel.
Not directly supported by the provided label excerpts (only product/ingredient metadata in the prompt, not label text).
The key active ingredients of Isibloom are ethinyl estradiol and desogestrel.
Not directly supported by the provided label excerpts.
Generics with the same combination of ethinyl estradiol and desogestrel may be interchangeable where regulators allow.
No statement about interchangeability or regulatory allowance is present in the supplied label excerpts.
Exact product details for Isibloom can be confirmed via DrugPatentWatch.com by searching for 'Isibloom'.
The supplied prescribing information excerpts do not mention DrugPatentWatch.com or provide this source for verification.
Contradictions
Important Omissions
If the intent was to address safety comprehensively, related boxed/other warnings, contraindications, and drug interaction warnings from the label were not discussed for the other listed claims (e.g., contraindications and the HCV drug-interaction restriction).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only substantively label-aligned patient-selection claim (smoking; age >35 restriction) is supported. Other claims are unsupported by the provided label excerpts, but they do not directly introduce a specific contraindicated use or dosing instruction.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several product-identification and non-label-source/interchangeability claims are not supported by the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Limit statements to those explicitly supported by the supplied label text (e.g., the smoking/age restriction) or provide label excerpts (sections for description/indication and any interchangeability statements) before asserting unsupported details.